Karen G Potter, Ph.D.

Alpine Immune Sciences in IP matters related to its immunomodulatory fusion proteins, including its acquisition by Vertex Pharmaceuticals for $4.9 billion, a $1.5 billion deal with Horizon Therapeutics, and an $865 million deal with AbbVie.

Bristol Myers Squibb (BMS), and subsidiaries Juno Therapeutics, Inc. and Celgene Corporation, in IP matters related to their cell therapy products, including in support of BMS’s $74 billion acquisition of Celgene Corporation and Celgene Corporation’s $9 billion acquisition of Juno Therapeutics.

Pro bono support of CureCMT4J/Talia Duff Foundation in IP matters in support of research and development of a therapy for Charcot-Marie-Tooth Disease Type 4J.

Dynavax in IP matters related to its development and commercialization of innovative vaccines, including HEPLISAV-B and its advancing pipeline that leverage its CpG 1018® adjuvant.

Pro bono support of FAM177A1 Research Fund in IP matters in support of research and development of a therapy for disorders related to pathogenic variants of the FAM177A1 gene.

General Catalyst in IP due diligence related to its Series A investment in Georgiamune, a clinical stage biotechnology company founded to bring potentially life-saving immunotherapy to cancer and autoimmune patients.

Indapta Therapeutics in IP matters related to its NK cell therapy product for treating cancer and autoimmune diseases, including in support of its $50 million Series A financing.

Inhibrx Biosciences in IP matters related to its sdAb platform and multispecific antibody formats.

Pro bono diligence for the National Multiple Sclerosis Society of potential grantees to support MS research.

Rakuten Medical in IP matters related to its innovative cell targeting photoimmunotherapy and related series financings.